There is presently no treatment specifically approved to halt the neurological damage that continues for hours and days in the wake of a brain injury. But there is an already-approved compound that some scientists and clinicians believe will prove helpful. The backers of NeuroPharma are betting that a new formulation of cyclosporin, the drug long used to prevent rejection of transplanted organs, can be shown to have a beneficial effect on people with TBI.
Magle Stora Kyrkogata 6
S-223 50 Lund, Sweden
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.